Global Schaaf-Yang Syndrome Treatment Market, By Treatment (Physical therapy, Occupational Therapy, Speech Therapy), End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029
Schaaf-Yang Syndrome Treatment Market Analysis and Size
The schaaf-yang syndrome treatment market is expected to witness significant growth during the forecast period. The increase in the facilities for patients affected by this severe disease syndrome has been directly impacting the growth of schaaf-yang syndrome treatment market. The prevalence of Schaaf-Yang syndrome is less than 1/1,000,000 worldwide. Increasing need for an accurate and appropriate diagnosis for these conditions is expected to have a significant impact on the market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the schaaf-yang syndrome treatment market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Schaaf-Yang syndrome is a rare genetic disorder which is characterized by hypotonia, intellectual disability, developmental delay, and an autism spectrum disorder. This syndrome is caused by the genetic variants in MAGEL2 gene on chromosome 15. Most cases of this syndrome are from de novo mutation. This diseased condition is increasing and thus it is very important to the healthcare sector.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Treatment (Physical Therapy, Occupational Therapy, Speech Therapy),End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Teleflex, Incorporated. (U.S.), Shenzhen Mindray Bio-Medical Electronics Co Ltd (China), Virchow Biotech (India), Alexion Pharmaceuticals, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Vertex Pharmaceuticals Incorporated (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Amgen Inc. (U.S.), Jazz Pharmaceuticals, Inc. (U.S.), Pfizer Inc (U.S.), PerkinElmer Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), BioMarin (U.S.), Sarepta Therapeutics Inc. (U.S.), ICU Medical Inc (U.S.), Moog Inc. (U.S.), AVNS. (U.S.), Nipro (Japan), ATRICURE INC (U.S.)
|
|
Market Opportunities
|
|
Global Schaaf-Yang Syndrome Treatment Market Dynamics
Drivers
- Increase in Advanced Treatments
Different treatment procedures used in this disease are boosting the market growth. Treatments such as physical therapy, speech therapy and high-end genetic counseling in some cases increases the patients' recovery chances. Thus, it acts as a major driver in the market growth.
- Increasing Awareness of Healthcare Infrastructure
Another significant factor influencing the growth rate of schaaf-yang syndrome treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
Opportunities
- Increase in Obesity
Around 13% of adults in the world are witnessed as obese. Approximately 39% of adults in the world are considered to be overweight. Globally, one-in-five children and adolescents are overweight. It leaves a great impact on the growth of this market.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global schaaf-yang syndrome treatment market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.
Restraints/Challenges
- Lack of Awareness
The sales of potential products are not succeeding much due to the less awareness of the syndrome. Though effective treatments are available, but beliefs, poor inadequate communication between clinicians and patients, treatment adherence are the factors hindering the market growth.
- High Cost
The huge expenditure required for the treatment processes surely hamper the market growth. Several market players make huge investment in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This schaaf-yang syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the schaaf-yang syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Schaaf-Yang Syndrome Treatment Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period.
The load on healthcare facilities and professionals was growing in tandem with the rapid increase in patient numbers. Many hospitals have decided to cancel or postpone procedures. The pandemic had a mixed influence on the schaaf-yang syndrome treatment market. The epidemic has put a strain on the treatment procedures overall. As a result of the lockdown and travel restrictions, the number of hospitals has decreased and countless drives have been cancelled around the world.
Global Schaaf-Yang Syndrome Treatment Market Scope
The schaaf-yang syndrome treatment market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Physical therapy
- Occupational therapy
- Speech therapy
End-User
- Hospitals
- Research Institutes
- Specialty Clinics
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Schaaf-Yang Syndrome Treatment Market Regional Analysis/Insights
The schaaf-yang syndrome treatment market is analysed and market size insights and trends are provided by treatment, distribution channel and end-user as referenced above.
The major countries covered in the schaaf-yang syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America is dominating the market in the forecast period due to the prevalence of the disease.
Asia-Pacific is considered to have the most lucrative period due to increasing number of patient population and surging level of disposable income in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Schaaf-Yang Syndrome Treatment Market Share Analysis
The schaaf-yang syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to schaaf-yang syndrome treatment market
Key players operating in the schaaf-yang syndrome treatment market include:
- Teleflex, Incorporated. (U.S.)
- Shenzhen Mindray Bio-Medical Electronics Co Ltd (China)
- Virchow Biotech (India)
- Alexion Pharmaceuticals, Inc. (U.S.)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- Vertex Pharmaceuticals Incorporated (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Amgen Inc. (U.S.)
- Jazz Pharmaceuticals, Inc. (U.S.)
- Pfizer Inc (U.S.)
- PerkinElmer Inc (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- BioMarin (U.S.)
- Sarepta Therapeutics Inc. (U.S.)
- ICU Medical Inc (U.S.)
- Moog Inc. (U.S.)
- AVNS. (U.S.)
- Nipro (Japan)
- ATRICURE INC (U.S.)
SKU-